US Stock MarketDetailed Quotes
IMRX Immuneering
- 2.100
- -0.010-0.47%
Close Nov 22 16:00 ET
- 2.020
- -0.080-3.81%
Post 19:41 ET
65.21MMarket Cap-1065P/E (TTM)
2.250High2.061Low342.06KVolume2.160Open2.110Pre Close736.31KTurnover1.53%Turnover RatioLossP/E (Static)31.05MShares8.89052wk High1.13P/B47.02MFloat Cap1.00052wk Low--Dividend TTM22.39MShs Float33.990Historical High--Div YieldTTM8.98%Amplitude1.000Historical Low2.152Avg Price1Lot Size
Immuneering Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -12.02%-13.47M | -7.23%-11.53M | -7.44%-15.49M | -11.04%-48.97M | -0.23%-11.78M | -13.22%-12.03M | -13.75%-10.75M | -17.40%-14.42M | -42.95%-44.1M | -27.16%-11.75M |
| Net income from continuing operations | -15.90%-14.6M | -15.52%-14.08M | -5.17%-14.31M | -5.86%-53.47M | -13.88%-15.08M | 1.94%-12.6M | -5.74%-12.19M | -5.49%-13.6M | -50.63%-50.51M | -22.82%-13.25M |
| Operating gains losses | ---- | ---- | ---- | -23.81%3.94K | --2.46K | --0 | --817 | --666 | --5.17K | ---- |
| Depreciation and amortization | 12.45%96.27K | 14.37%97.85K | 16.32%97.53K | 26.99%352.08K | 15.32%97.07K | 13.56%85.61K | 203.15%85.56K | -58.21%83.84K | 74.29%277.25K | 60.35%84.18K |
| Change In working capital | 17.25%-657.59K | 2,577.24%724.49K | -28.38%-2.68M | -156.76%-974.64K | 297.65%1.88M | -175.85%-794.68K | -96.54%27.06K | -256.48%-2.09M | 90.72%1.72M | -54.72%473.7K |
| -Change in receivables | --0 | --0 | --0 | -94.69%12.42K | --0 | --0 | -98.97%1.05K | 133.87%11.37K | -16.48%233.62K | -76.98%57.76K |
| -Change in prepaid assets | 21.25%-644.55K | -550.66%-788.13K | -51.47%248.9K | 39.28%-172.66K | 90.69%-41.95K | 55.99%-818.49K | -71.67%174.88K | -63.60%512.9K | 88.20%-284.35K | -163.17%-450.76K |
| -Change in payables and accrued expense | 117.96%156.22K | 3,644.43%1.74M | -4.79%-2.65M | -117.22%-384.91K | 133.84%2.12M | -97.77%71.68K | -146.39%-49.06K | -27.02%-2.52M | -28.15%2.23M | 753.44%905.21K |
| -Change in other current assets | ---67.69K | ---223.64K | --30K | 19.28%-290.74K | -7,020.79%-290.74K | --0 | --0 | --0 | ---360.2K | ---4.08K |
| -Change in other current liabilities | -112.21%-101.57K | 97.36%-2.64K | -250.60%-317.84K | -30.18%-138.75K | 389.22%99.58K | -10.99%-47.87K | -138.26%-99.81K | -804.94%-90.66K | -31.83%-106.59K | -40.39%-34.43K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -12.02%-13.47M | -7.23%-11.53M | -7.44%-15.49M | -11.04%-48.97M | -0.23%-11.78M | -13.22%-12.03M | -13.75%-10.75M | -17.40%-14.42M | -42.95%-44.1M | -27.16%-11.75M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 77.41%-5.42M | -45.79%4.97M | 12.76%21.39M | -82.56%7.3M | -61.57%3.13M | -2,623.83%-23.97M | -58.64%9.16M | 52.94%18.97M | 155.32%41.83M | 135.74%8.15M |
| Net PPE purchase and sale | 90.78%-5.27K | 62.19%-32.77K | -33.88%-37.48K | 53.84%-342.75K | -146.63%-170.92K | 85.46%-57.15K | 47.46%-86.69K | 75.67%-27.99K | -1,121.47%-742.48K | -430.97%-69.3K |
| Net investment purchase and sale | 77.38%-5.41M | -45.95%5M | 12.79%21.43M | -82.06%7.64M | -59.82%3.3M | -4,811.18%-23.91M | -58.56%9.25M | 51.76%19M | 156.30%42.57M | 135.96%8.22M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 77.41%-5.42M | -45.79%4.97M | 12.76%21.39M | -82.56%7.3M | -61.57%3.13M | -2,623.83%-23.97M | -58.64%9.16M | 52.94%18.97M | 155.32%41.83M | 135.74%8.15M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 20,249.61%4.36M | 0 | 309.31%979.92K | 149,558.35%28.44M | 104.24%7.84K | 224.60%21.45K | 101,297.86%28.17M | 23.97%239.41K | -99.99%19K | -2,556.14%-184.68K |
| Net common stock issuance | --4.24M | ---- | ---- | --28.2M | --0 | --0 | ---- | ---- | --0 | --0 |
| Proceeds from stock option exercised by employees | 493.00%127.19K | --0 | 309.31%979.92K | 48.09%444.84K | -81.39%7.84K | -42.63%21.45K | 533.99%176.15K | 23.97%239.41K | -76.56%300.38K | 459.89%42.1K |
| Net other financing activities | ---- | ---- | ---- | 27.58%-203.77K | --0 | --0 | ---- | ---- | 86.75%-281.38K | ---226.78K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 20,249.61%4.36M | --0 | 309.31%979.92K | 149,558.35%28.44M | 104.24%7.84K | 224.60%21.45K | 101,297.86%28.17M | 23.97%239.41K | -99.99%19K | -2,556.14%-184.68K |
| Net cash flow | ||||||||||
| Beginning cash position | -42.58%59.73M | -14.39%66.29M | -18.22%59.41M | -3.01%72.64M | -10.96%68.04M | 18.29%104.02M | 2.96%77.43M | -3.01%72.64M | 101.91%74.89M | -28.53%76.42M |
| Current changes in cash | 59.63%-14.52M | -124.67%-6.56M | 43.56%6.88M | -487.72%-13.23M | -128.37%-8.63M | -212.31%-35.98M | 108.82%26.59M | 1,412.52%4.79M | -105.96%-2.25M | 88.20%-3.78M |
| End cash Position | -33.56%45.21M | -42.58%59.73M | -14.39%66.29M | -18.22%59.41M | -18.22%59.41M | -10.96%68.04M | 18.29%104.02M | 2.96%77.43M | -3.01%72.64M | -3.01%72.64M |
| Free cash flow | -11.53%-13.48M | -6.68%-11.56M | -7.49%-15.53M | -9.96%-49.31M | -1.08%-11.95M | -9.70%-12.08M | -12.70%-10.84M | -16.54%-14.45M | -45.07%-44.84M | -27.73%-11.82M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data